Actively Recruiting
Mitochondrial Substrate Utilization in the Diabetic Human Heart
Led by Heinrich-Heine University, Duesseldorf · Updated on 2026-02-19
500
Participants Needed
1
Research Sites
704 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Diabetes can lead to heart failure independently, but the underlying causes remain incompletely understood. The main aim of this study is to identify differential regulation of mitochondrial substrate utilization and complex activity in heart failure and type 2 diabetes mellitus (T2DM). For this, we will conduct a prospective, observational study to examine myocardial mitochondrial oxidative function and related metabolic parameters, gene expression, histological markers, and inflammation in cardiac tissue from patients with heart failure or patients after heart transplantation. We will further assess cardiac function using cardiac magnetic resonance imaging with and without stress protocols and magnetic resonance spectroscopy. Glycemic control/T2DM will be characterized by oral glucose tolerance tests. The results of this project will help to better understand the cellular mechanisms of the development of diabetic cardiomyopathy and contribute to the development of early diagnostic, as well as therapeutic approaches for the prevention and treatment of diabetic cardiomyopathy.
CONDITIONS
Official Title
Mitochondrial Substrate Utilization in the Diabetic Human Heart
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 20 to 85 years
- Male and female patients with manifest heart failure (NYHA II-IV) and clinical indication for myocardial biopsy or after transplantation and clinical indication for myocardial biopsy with or without type II diabetes mellitus or terminal (NYHA IV) heart failure with or without type II diabetes mellitus
- Written informed consent
You will not qualify if you...
- Acute infectious diseases within the last 2 weeks before the examination
- Autoimmune diseases or acute immunocompromising diseases (leukocytes < 5000/µl)
- Pregnancy
- Use of alcohol or drugs (addiction), psychiatric diseases
- Suspected or manifest AIDS (HIV); hepatitis B or C
- Liver disease not attributed to nonalcoholic fatty liver hepatitis or congestive hepatopathy in heart failure
- Malignant cancer
- Lack of capacity to give informed consent or lack of consent to participate in the study
- Contraindications to regadenoson for MRI stress test such as hypersensitivity, certain heart conduction blocks without pacemaker, unstable angina, severe hypotension, or decompensated heart failure
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University-Hospital Düsseldorf Division of Cardiology, Pulmonary Disease and Vascular Medicine
Düsseldorf, Germany, 40225
Actively Recruiting
Research Team
E
Elric Zweck, MD
CONTACT
A
Amin Polzin, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here